tailieunhanh - Báo cáo khoa học: "Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. | Available online http content 10 6 R177 Research Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage Lars Heslet1 Jorn Dalsgaard Nielsen2 Marcel Levi3 Henrik Sengelov4 and Par I Johansson5 1 Department of Intensive Care ITA 4131 University Hospital of Copenhagen Rigshospitalet Blegdamsvej 9 DK 2100 Denmark 2Department of Clinical Biochemistry Gentofte University Hospital Niels Andersens Vej 65 DK 2900 Hellerup Denmark Department of Internal Medicine Vascular Medicine Amsterdam Medical Center De Boelelaan 1117 1081 HV Amsterdam The Netherlands 4Department of Hematology H University Hospital of Copenhagen Rigshospitalet Blegdamsvej 9 DK 2100 Denmark 5Department of Clinical Immunology University Hospital of Copenhagen Rigshospitalet Blegdamsvej 9 DK 21 00 Denmark Corresponding author Lars Heslet heslet@ Received 5 Oct 2006 Revisions requested 9 Nov 2006 Revisions received 5 Dec 2006 Accepted 21 Dec 2006 Published 21 Dec 2006 Critical Care 2006 10 R177 doi cc5132 This article is online at http content 10 6 R1 77 2006 Heslet et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction Diffuse alveolar hemorrhage DAH is a serious pulmonary complication seen in patients with autoimmune disorders and patients treated with chemotherapy or after hematopoietic stem cell transplantation. The clinical management of DAH is complex and the condition has a high mortality rate. Tissue factor is expressed in the lung alveoli during inflammation and therefore pulmonary administration of human recombinant activated factor VIIa rFVIIa could be a rational treatment option. Methods Six patients with acute bronchoscopically confirmed